About David Bearss
David Bearss is a co-founder · chairman at Biolexis Therapeutics.
Form D filings also name David Bearss as a chief executive officer and director at Halia Therapeutics, a director at Canary Speech and Reglagene and an executive officer and director at Xenter.
David Bearss first appears on SEC filings in 2020.
Experience
This experience comes from David Bearss's profile and from SEC filings. For roles taken from filings, the years are when the filings name David Bearss in the role, so the role may have started earlier or lasted longer.
BI
BioUtah Current
Vice Chairman of the Board
2023 – Present
UC
UVB Capital Current
Partner
2023 – Present
Biolexis Therapeutics Inc. Current
Co-founder · Chairman
Co-Founder and Chairman (2021 – Present)
2021 – Present · Lehi, UT
Develops oral drug candidates for people with obesity and type 2 diabetes.
Halia Therapeutics, Inc. Current
Co-Founder, CEO and President (2020 – Present)
Director
2020 – Present · Lehi, UT
Develops investigational drugs for people with inflammatory and neurological diseases.
UU
University of Utah Current
Senior Managing Director U2TAH Therapeutics Accelerator
2004 – Present
SO
Systems Oncology
Scientific Advisor
2020 – 2024
SV
Scientia Vascular
Board Member
2019 – 2022
SO
Sumitomo Dainippon Pharma Oncology
CSO and Global Head of Research, SDP Oncology
2020
DP
Dainippon Sumitomo Pharma
Chief Scientific Advisor, Sumitomo Dainippon Pharma Cancer Institute, Osaka, Japan
2018 – 2020
TI
Tolero Pharmaceuticals, Inc.
Founder and CEO
2011 – 2020
WS
Wasatch Scientific
Co-Founder
2013 – 2018
TL
Tetragene LLC
Founder and Chairman
2012 – 2017
BU
Brigham Young University
Associate Professor, Department of Physiology and Developmental Biology
2012 – 2013
NP
Nuskin & Pharmanex
Scientific Advisory Board
2011 – 2013
HI
Huntsman Cancer Institute
Co-director of the Center for Investigational Therapeutics
2009 – 2012
Key Colleagues at Startups
The people David Bearss works with at each company, as listed on that company's latest Form D.
Halia Therapeutics, Inc. · Form D, Aug 31, 2026
Preston Campbell
Director
MB
Mary Beckerle
Director
David Checketts
Director
Gary Sabin
Executive Chairman
Jeffrey Burton
Chief Financial Officer
John Kauwe
Co-Founder and director
Biolexis Therapeutics Inc. · Form D, Jun 3, 2026
Tyler Hartmann
President
Hariprasad Vankayalapati
Co-founder · Chief Scientific Officer and director
JC
James Clarke
Director
AS
Anthony Steve
Director
Canary Speech Inc. · Form D, May 17, 2023
JM
Jeremy McFadden
Executive officer
JA
Jeff Adams
Director
RK
Rick Kreifeldt
Director
TP
Trent Perry
Director
HC
Henry O'Connell
Chief Executive Officer and director
WI
William Perry IV
Director
Xenter, Inc. · Form D, Jul 14, 2021
EE
Elazer Edelman
Director
MS
Mark Stautberg
Director
DS
David Sampson
Executive officer
JT
James Tobin
Director
RB
Robert Baxter
Executive officer and director
RL
Richard Linder
Executive officer and director
Robert Langer
Director
EP
Eric Pearson
Exec VP & General Counsel
Reglagene, Inc. · Form D, Jul 13, 2021
SA
Sharon Ayd
Director
LH
Laurence Hurley
Director
LK
Lawrence Kinet
Director
RA
Richard Austin
President and director